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LETTERS TO THE EDITOR
Identity, Similarity,
and Difference
between Large Cell
Neuroendocrine
Carcinoma and Small
Cell Carcinoma
To the Editor:
I read the article entitled “Should
large cell neuroendocrine lung carcinoma
be classified and treated as a small cell
lung cancer or with other large cell carci-
nomas?” by Varlotto et al.1 with great
interest. Knowing that the World Health
Organization classification for the lung tu-
mors is being revised, how to deal with the
tumors with neuroendocrine features/mor-
phology is one of the greatest issues in the
revision process, and it remains as a great
concern to not only pathologists but also
many clinicians.
In this retrospective study, the au-
thors retrieved 1211 patients with large
cell neuroendocrine carcinoma (LCNEC),
8295 patients with other large cell carci-
nomas (OLC), and 35,304 patients with
small cell lung carcinoma (SCLC) from
the Surveillance Epidemiology and End
Results (SEER) database from 2001
through 2007. They focused on the demo-
graphic and prognostic (overall survival
and lung cancer-specific survival) differ-
ences among these three histologic types.
The authors concluded that the clinical,
histopathologic, and biologic features of
LCNEC were more similar to OLC than
to SCLC.
On the other hand, we have com-
pared the demographics and prognosis
of 141 LCNECs, 113 SCLCs, and other
lung tumors with/without neuroendo-
crine features including 33 large cell
carcinomas.2 These cases were all re-
sected surgically with enough speci-
mens for central pathologic review by
expert panel. The results indicated that
LCNEC and SCLC share the common
demographic background and progno-
ses, and therefore, we have concluded
that these two histologies belong to the
same high-grade neuroendocrine tumors
of the lung. This was an opposite con-
clusion to the study by Varlotto et al.
In discussing the similarities/dif-
ferences among different histopatho-
logic types, the establishment of the cor-
rect, reliable diagnosis is a key issue.
Especially for the diagnosis of tumors
with neuroendocrine morphology/phe-
notype, the diagnosis needs to demon-
strate not only the histopathologic neu-
roendocrine morphology but also the
neuroendocrine phenotype by electron
microscope or immunohistochemistry.
As for LCNEC, the morphology is to be
characterized by the organoid nesting,
trabecular growth, rosette formation,
palisading, necrosis, and high mitotic
figures.3 The World Health Organization
classification further strictly requires the
immunohistochemistry using neuroen-
docrine markers such as chromogranin,
synaptophysin, and neural cell adhesion
molecule. The demonstration of specific
neuroamines, neuropeptide, or hormone
is also permitted. In our previous study,
such process was all centralized with the
review by expert pathologists to confirm
the neuroendocrine morphology/phenotype.
Herein, I raise the question regard-
ing the histologic diagnosis in the study
by Varlotto et al. The authors used the
registry data of SEER simply with the
code of histologic diagnosis as
“LCNEC,” “OLC,” or “SCLC.” How-
ever, how strictly were these diagnosis
made? How sure were they? As was
written by the authors, “distinguishing
LCNEC from SCLC can occasionally be
difficult,” even with the aid of the im-
munohistochemical study, and the qual-
ity of diagnosis wholly depends on how
strictly each histologic criterion was ex-
amined. In the SEER database, it might
have happened that number of cases
currently classified as LCNEC could
have been previously included in the
SCLC or OLC category and vice versa.
According to the authors, “such misclas-
sification could potentially mask differ-
ences in presenting characteristics and
outcome between LCNEC and SCLC.”
This is really a crucial point especially
in discussing the biological identity,
similarity, and difference among differ-
ent morphologies. The issue in the arti-
cle by Varlotto et al. is the reliability of
the histologic diagnosis because of the
nature of the data, a registry database.
In our previous study, both LCNEC
and SCLC could be characterized as the
high-grade neuroendocrine carcinoma.
They were more likely to arise among
elderly men (LCNEC, 89.4%; SCLC,
79.9%) with heavy smoking history
(LCNEC, 98.6%; SCLC, 93.8%). These
similar backgrounds and prognoses of two
different histologies have suggested that
these tumors are closely located in the
malignant spectrum of the lung tumors
despite the morphologic difference.4 In
the study by Varlotto et al., however,
men comprised only 55.2% of LCNEC
and 48.5% of SCLC, and the smoking
history was not clearly shown. Looking at
these data, I am not sure whether tumors
in our previous study were really same as
those in the study by Varlotto et al.
How to deal both LCNEC and
SCLC with neuroendocrine features in
the classification of the lung tumors is
relevant to how to manage the patients
with these histologies. The present ther-
apeutic schema is wholly based on the
histology as SCLC or non-small cell
carcinoma, and therefore, the clinicians
are very much concerned about the fu-
ture revision of the histologic classifica-
tion of lung tumors.
Hisao Asamura, MD
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Tokyo, Japan
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